**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 75-year-old woman developed hypoglycaemia during off-label treatment with hydroxychloroquine for coronavirus infection-2019 (COVID-19). Additionally, she received off-label treatment with azithromycin, oseltamivir and piperacillin/tazobactam for COVID-19 infection \[*not all dosages stated; routes not stated*\].

The woman, who had metastatic malignant melanoma, was admitted to emergency department (ED) with severe fatigue and fever on 16 March 2020. She had multiple co-morbidities. She had underwent surgery and received treatment with nivolumab. On admission to ED, she had mild dyspnoea and decreased oxygen saturation. An empirical treatment with piperacillin/tazobactam was started for high fever. On 17 March 2020, she was hospitalised. Concomitantly, she received fluconazole for *Candida albicans* infection. On 18 March 2020, she was diagnosed with COVID-19 infection. She was then transferred to COVID-19 clinic and quarantined. Additionally, she started receiving oseltamivir 75mg twice a day along with clarithromycin for community-acquired pneumonia and empirical metronidazole was added for diarrhoea. On 18 March 2020, an initial result of COVID-19 real time PCR was negative. However, on 20 March 2020, the second real time-PCR result was positive. Subsequently, she was started on off-label treatment with hydroxychloroquine 200mg twice a day. Also, treatment with clarithromycin was stopped, and azithromycin was started for COVID-19. On the second day of the hydroxychloroquine treatment (on 22 March 2020), she developed hypoglycaemia. All her oral anti-diabetics were stopped due to hypoglycaemia. There was no other risk factor for the hypoglycaemia. Hypoglycaemia was considered as a side effect of hydroxychloroquine \[*outcome not stated*\]. As no other option was available, treatment with hydroxychloroquine was continued. Her oxygen saturation level improved and diarrhoea resolved. As fifth day of the COVID-19 treatment, she was receiving oseltamivir, azithromycin, hydroxychloroquine, and piperacillin/tazobactam as off-label treatment. At this time, a chest CT scan showed only bilateral minimal pleural effusion. There were no characteristic findings of the COVID-19. Therefore, on day 5, the COVID-19 treatment was discontinued due to the resolving clinical findings. On 28 March 2020, she presented with mild hypoxia. A pulmonary CT scan showed mild ground glass opacity areas in the lung parenchyma. Therefore, she was restarted on hydroxychloroquine 200mg twice a day along with favipiravir for COVID-19 pneumonia. On 01 April 2020, her oxygen requirement decreased. The COVID-19 treatment was discontinued and she was discharged. Ten days after the discharge, she died due to her unspecified chronic cardiac problems.
